Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated November 19, 2024, discloses insider trading activity in compliance with Article 19 of Regulation No. 596/2014 on market abuse. The company is a leading global healthcare firm headquartered in Denmark, employing approximately 72,000 people across 80 countries.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It solely reports on a specific equity transaction.
| Transaction Type | Instrument | Volume | Price (DKK) | Total Value (DKK) |
|---|---|---|---|---|
| Purchase | ADRs (NVO) | 2,500 | 709.25 | 1,773,118.70 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document serves as a regulatory notification of an executive's personal share purchase.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a standard disclosure of a transaction executed on November 18, 2024, on the New York Stock Exchange by David Moore, Executive Vice President and Head of Corporate Development.
Key Facts for Investor Verification
- David Moore, an executive, purchased 2,500 ADRs at DKK 709.25 per share.
- The transaction occurred on November 18, 2024, on the NYSE.
- The total value of the transaction was approximately DKK 1.77 million.
- This filing does not contain quarterly or annual financial results.